AMENDMENTS TO THE CLAIMS

After entering the Substitute Specification, please amend claims 1, 5, 8, and 12, and add new claims 17-24, as provided in the following listing of claims, which will replace all prior versions and listings of claims in the application. Please cancel claims 3, 6, 7, and 13-16 without prejudice to their pursuit in an appropriate continuation or divisional application.

In the claims:

1 (currently amended). A method ~~to produce~~of producing one or more cDNA molecules comprising:

(a) contacting a sample comprising a cell or a virus with a solid medium, wherein:

(i) the sample comprises mRNA and genomic DNA;

(ii) the mRNA comprises an mRNA -template ~~with a solid medium,~~ of interest; and

(iii) wherein the solid medium comprises:

~~(i)~~ a matrix; and

~~(ii)~~ a composition for inhibiting degradation of the mRNA template, wherein:

- the composition comprises a detergent or surfactant; and
- the composition is sorbed to the matrix then dried prior to contact with the sample;

(b) sorbing at least a portion of the mRNA template to the solid medium;

(c) eluting the mRNA from the solid medium while retaining the genomic DNA; and

~~(c)~~(d) contacting the ~~template~~ mRNA with one or more reverse transcriptases under conditions sufficient to synthesize one or more cDNA molecules complementary to all or a portion of the mRNA template of interest.

2 (previously presented). The method of claim 1, wherein the cDNA is a cDNA library.

3 (canceled).

4 (previously presented). The method of claim 1, wherein the cDNA is double-stranded.

5 (currently amended). The method of claim 1, further comprising:

(~~d~~e) amplifying the cDNA.

6. - 7. (canceled)

8 (currently amended). The method of claim 1, wherein ~~the matrix contains a composition for substantially inhibiting degradation of the mRNA template,~~ the detergent or surfactant of the composition is an anionic detergent or surfactant and wherein the composition ~~comprising~~further comprises:

(a) a base; and

(b) a chelating agent~~; and~~

~~(c) an anionic detergent or surfactant~~.

9 (previously presented). The method of claim 8, wherein the composition further comprises uric acid or a urate salt.

10 (previously presented). The method of claim 1, wherein the matrix comprises a cellulose-based matrix or paper, or a micromesh of synthetic plastic material.

11 (previously presented). The method of claim 1, wherein the matrix is selected from the group consisting of nitrocellulose, cellulose, diazocellulose, carboxymethylcellulose, hydrophilic polymers, polytetra-fluoro-ethylene, fiberglass, porous ceramics, polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, agarose, agar, starch, and nylon.

12 (previously presented). The method of claim 1, wherein the sample ~~comprising the mRNA template is selected from the group consisting of cells, viruses, viral plaques, and preparations from biological materials~~comprises a eukaryotic cell.

13 - 16 (canceled).

17 (new). The method of claim 5, wherein the amplifying step comprises contacting at least one cDNA strand with a polymerase under conditions to synthesize one or more cDNA molecules complementary to all or a portion of the template.

18 (new). The method of claim 5, wherein the amplifying step comprises a polymerase chain reaction (PCR).

19 (new). The method of claim 8, wherein:

(a) the anionic detergent or surfactant comprises sodium dodecyl sulfate (SDS);

(b) the base comprises Tris or tris-hydroxymethyl methane; and

(c) the chelating agent comprises ethylene diamine tetra-acetic acid (EDTA).

20 (new). The method of claim 1, wherein the eluting step further comprises contacting the solid medium comprising the mRNA with an elution buffer, wherein the elution buffer comprises:

(a) a base;

(b) a chelating agent;

(c) dithiothreitol; and

(d) a ribonuclease inhibitor.

21 (new). The method of claim 20, wherein the elution buffer further comprises:

(e) glycogen.

22 (new). The method of claim 20, wherein:

(a) the base comprises Tris or tris-hydroxymethyl methane; and

(b) the chelating agent comprises ethylene diamine tetra-acetic acid (EDTA).

23 (new). The method of claim 20, wherein the eluting step further comprises incubating the solid medium comprising the mRNA with the elution buffer at a temperature at or below 4°C.

24 (new). The method of claim 20, wherein the eluting step further comprises vortexing the solid medium comprising the mRNA with the elution buffer.